These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 3010124)

  • 21. Minimal tumor necrosis factor receptor binding protein: optimum biological activity of a truncated p55 soluble tumor necrosis factor receptor-IgG fusion protein.
    Corcoran AE; Scallon BJ; Trinh H; Chernajovsky Y; Ghrayeb J; Feldmann M
    Eur Cytokine Netw; 1998 Sep; 9(3):255-62. PubMed ID: 9831174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumour necrosis factor. Polypeptide mediator network.
    Old LJ
    Nature; 1987 Mar 26-Apr 1; 326(6111):330-1. PubMed ID: 3494200
    [No Abstract]   [Full Text] [Related]  

  • 23. The divergent effects of tumour necrosis factor-alpha on skeletal muscle: implications in wasting.
    Argilés JM; Alvarez B; Carbó N; Busquets S; Van Royen M; López-Soriano FJ
    Eur Cytokine Netw; 2000 Dec; 11(4):552-9. PubMed ID: 11125297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cachectin in tissue injury, shock, and related states.
    Beutler B
    Crit Care Clin; 1989 Apr; 5(2):353-67. PubMed ID: 2650822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Tumor necrosis factor and cachectin. The same hormone with multiple effects].
    Sappino AP; Alberto P
    Ann Pathol; 1987; 7(4-5):239-41. PubMed ID: 3435616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumour necrosis factor and lymphotoxin genes map close to H-2D in the mouse major histocompatibility complex.
    Müller U; Jongeneel CV; Nedospasov SA; Lindahl KF; Steinmetz M
    Nature; 1987 Jan 15-21; 325(6101):265-7. PubMed ID: 3027565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system.
    Warzocha K; Bienvenu J; Coiffier B; Salles G
    Eur Cytokine Netw; 1995; 6(2):83-96. PubMed ID: 7578992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cachectin/tumor necrosis factor: an endogenous mediator of shock and inflammation.
    Beutler B; Cerami A
    Immunol Res; 1986; 5(4):281-93. PubMed ID: 3036973
    [No Abstract]   [Full Text] [Related]  

  • 29. Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins.
    Scallon BJ; Trinh H; Nedelman M; Brennan FM; Feldmann M; Ghrayeb J
    Cytokine; 1995 Nov; 7(8):759-70. PubMed ID: 8664442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor necrosis factor as a pharmacological target.
    Ghezzi P; Cerami A
    Methods Mol Med; 2004; 98():1-8. PubMed ID: 15064428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-function analysis of an evolutionary conserved protein, DAP3, which mediates TNF-alpha- and Fas-induced cell death.
    Kissil JL; Cohen O; Raveh T; Kimchi A
    EMBO J; 1999 Jan; 18(2):353-62. PubMed ID: 9889192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disparate effects of tumor necrosis factor-alpha/cachectin and tumor necrosis factor-beta/lymphotoxin on hematopoietic growth factor production and neutrophil adhesion molecule expression by cultured human endothelial cells.
    Broudy VC; Harlan JM; Adamson JW
    J Immunol; 1987 Jun; 138(12):4298-302. PubMed ID: 3495589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rheumatoid arthritis synovial fluid macrophages express decreased tumor necrosis factor-related apoptosis-inducing ligand R2 and increased decoy receptor tumor necrosis factor-related apoptosis-inducing ligand R3.
    Perlman H; Nguyen N; Liu H; Eslick J; Esser S; Walsh K; Moore TL; Pope RM
    Arthritis Rheum; 2003 Nov; 48(11):3096-101. PubMed ID: 14613271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mouse lymphotoxin-beta receptor. Molecular genetics, ligand binding, and expression.
    Force WR; Walter BN; Hession C; Tizard R; Kozak CA; Browning JL; Ware CF
    J Immunol; 1995 Dec; 155(11):5280-8. PubMed ID: 7594541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin 1, tumour necrosis factor-alpha (cachectin) and the pathogenesis of cancer cachexia.
    Moldawer LL; Georgieff M; Lundholm K
    Clin Physiol; 1987 Aug; 7(4):263-74. PubMed ID: 3304809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cachectin: a hormone that triggers acute shock and chronic cachexia.
    Tracey KJ; Lowry SF; Cerami A
    J Infect Dis; 1988 Mar; 157(3):413-20. PubMed ID: 3278061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin.
    Pennica D; Nedwin GE; Hayflick JS; Seeburg PH; Derynck R; Palladino MA; Kohr WJ; Aggarwal BB; Goeddel DV
    Nature; 1984 Dec 20-1985 Jan 2; 312(5996):724-9. PubMed ID: 6392892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytotoxins (tumour necrosis factor, lymphotoxin and others): molecular and functional characteristics and interactions with interferons.
    Wallach D
    Interferon; 1986; 7():89-124. PubMed ID: 2434436
    [No Abstract]   [Full Text] [Related]  

  • 39. The biology of cachectin/TNF--a primary mediator of the host response.
    Beutler B; Cerami A
    Annu Rev Immunol; 1989; 7():625-55. PubMed ID: 2540776
    [No Abstract]   [Full Text] [Related]  

  • 40. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor).
    Cerami A; Ikeda Y; Le Trang N; Hotez PJ; Beutler B
    Immunol Lett; 1985; 11(3-4):173-7. PubMed ID: 3910566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.